Related Experiment Video
Updated: Sep 21, 2025

Th17 Inflammation Model of Oropharyngeal Candidiasis in Immunodeficient Mice
Published on: February 18, 2015
Cryptococcal meningitis associated with interleukin-17 inhibitor use for psoriasis
Joseph Driver1, Marcus Zaayman2, Annika Silfvast-Kaiser3
1College of Medicine, Texas A&M University, Dallas, Texas, USA.
Abstract:
Invasive fungal infection is a rare but serious potential consequence of biologic therapy. Herein, we report a case of cryptococcal meningitis in an otherwise immunocompetent patient receiving ixekizumab for the treatment of severe plaque psoriasis. We also discuss the relevant immunologic role of interleukin-17, the potential for synergistic effects when transitioning biologic therapies, and clinical considerations when treating patients with such medications. To the best of our knowledge, this is the first case of cryptococcal meningitis reported in a patient treated with ixekizumab.
Insights
Invasive fungal infections are a rare risk of biologic therapy. This case highlights cryptococcal meningitis in an immunocompetent patient on ixekizumab for psoriasis, emphasizing IL-17
Area of Science:
- Immunology
- Dermatology
- Infectious Diseases
Background:
- Biologic therapies, particularly those targeting interleukin-17 (IL-17), are effective for severe plaque psoriasis.
- While generally safe, invasive fungal infections are a rare but serious potential complication of immunosuppressive biologic treatments.
Observation:
- A case of cryptococcal meningitis is presented in an otherwise immunocompetent patient undergoing treatment with ixekizumab for severe plaque psoriasis.
- This patient experienced a severe fungal infection despite no apparent underlying immunodeficiency.
Findings:
- This report details the first known instance of cryptococcal meningitis associated with ixekizumab therapy.
- The case underscores the potential for invasive fungal infections even in patients considered immunocompetent.
Implications:
- Clinicians should maintain vigilance for invasive fungal infections in patients receiving IL-17 inhibitors like ixekizumab.
- Understanding the immunologic role of IL-17 is crucial for managing risks associated with biologic therapies and therapy transitions.
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Fungal Phylum Microsporidia

